美可保健公司辩解说,辉瑞的项目是为各方省钱,并保证稳定供货。
Others fear that Pfizer s tactics may drive up costs for the employers who sponsor healthplans, thanks to the complexities of co-payment schemes, and confuse patients lectured foryears about the merits of generics.
也有人担心,由于共同支付计划很复杂,辉瑞的战术会增加雇主门支付健康计划的成本,也让患者们在数年内都不明白仿制药的重要意义。
Express Scripts is advising the health plans it works for to reject Pfizer s deals for Lipitor.
快捷药方公司正建议其所属的健康计划反对辉瑞的立普妥交易。
The biggest worry is that Pfizer s strategy, if copied, will make the 180-day exclusivityperiod worth far less, and thus discourage generics firms from challenging patents in thefirst place.
他们最担心,如若辉瑞的做法被仿制,那么180天专有期的价值会缩水,而仿制药公司挑战专利的动力也会在初期被抑制。
【2015考研英语阅读制药企业悬念】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30